StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) stock

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

Inhibitor Therapeutics cash

Cash and short-term investments held at the end of each period.

Inhibitor Therapeutics's cash was $515.76K at Jun 30, 2026. For fiscal 2025 it was $2.38M, down 57.6% from the year before. Over ten years it grew 14.7% a year on average. The highest annual figure on record is $11.95M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.38M-57.6%
FY2024Dec 31, 2024$5.61M-36.6%
FY2023Dec 31, 2023$8.84M-26.0%
FY2022Dec 31, 2022$11.95M+38923.1%
FY2021Dec 31, 2021$30.63K-59.2%
FY2020Dec 31, 2020$75.06K-90.7%
FY2019Dec 31, 2019$803.82K-27.5%
FY2018Dec 31, 2018$1.11M+222.2%
FY2017Dec 31, 2017$344.11K-95.0%
FY2016Dec 31, 2016$6.89M+1044.8%
FY2015Dec 31, 2015$601.45K+64.7%
FY2014Dec 31, 2014$365.16K+168177.0%
FY2013Dec 31, 2013$217-100.0%
FY2012Dec 31, 2012$857.70K-35.1%
FY2011Dec 31, 2011$1.32M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$515.76K-86.2%
Q1 FY2026Mar 31, 2026$1.29M-70.1%
Q4 FY2025Dec 31, 2025$2.38M-57.6%
Q3 FY2025Sep 30, 2025$2.98M-53.3%
Q2 FY2025Jun 30, 2025$3.74M-47.3%
Q1 FY2025Mar 31, 2025$4.32M-43.7%
Q4 FY2024Dec 31, 2024$5.61M-36.6%
Q3 FY2024Sep 30, 2024$6.38M-33.1%
Q2 FY2024Jun 30, 2024$7.10M-29.7%
Q1 FY2024Mar 31, 2024$7.68M-28.8%
Q4 FY2023Dec 31, 2023$8.84M-26.0%
Q3 FY2023Sep 30, 2023$9.54M+17875.8%
Q2 FY2023Jun 30, 2023$10.10M+40390.4%
Q1 FY2023Mar 31, 2023$10.78M+29492.6%
Q4 FY2022Dec 31, 2022$11.95M+38923.1%
Q3 FY2022Sep 30, 2022$53.06K-0.4%
Q2 FY2022Jun 30, 2022$24.95K-73.4%
Q1 FY2022Mar 31, 2022$36.44K-56.7%
Q4 FY2021Dec 31, 2021$30.63K-59.2%
Q3 FY2021Sep 30, 2021$53.29K+45.2%
Q2 FY2021Jun 30, 2021$93.72K-31.8%
Q1 FY2021Mar 31, 2021$84.19K-72.2%
Q4 FY2020Dec 31, 2020$75.06K-90.7%
Q3 FY2020Sep 30, 2020$36.71K-97.3%
Q2 FY2020Jun 30, 2020$137.32K-93.2%
Q1 FY2020Mar 31, 2020$302.69K-73.2%
Q4 FY2019Dec 31, 2019$803.82K-27.5%
Q3 FY2019Sep 30, 2019$1.37M-4.8%
Q2 FY2019Jun 30, 2019$2.03M+154.5%
Q1 FY2019Mar 31, 2019$1.13M-28.1%
Q4 FY2018Dec 31, 2018$1.11M+222.2%
Q3 FY2018Sep 30, 2018$1.44M+62.4%
Q2 FY2018Jun 30, 2018$795.76K-51.6%
Q1 FY2018Mar 31, 2018$1.57M-32.8%
Q4 FY2017Dec 31, 2017$344.11K-95.0%
Q3 FY2017Sep 30, 2017$887.36K-75.0%
Q2 FY2017Jun 30, 2017$1.64M–
Q1 FY2017Mar 31, 2017$2.34M–
Q4 FY2016Dec 31, 2016$6.89M–
Q3 FY2016Sep 30, 2016$3.55M–

More Inhibitor Therapeutics figures

See a number that looks wrong?